Ascendis Pharma A (ASND) Debt to Equity (2021 - 2025)
Historic Debt to Equity for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to -$5.0.
- Ascendis Pharma A's Debt to Equity rose 3575.99% to -$5.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$5.0, marking a year-over-year increase of 3575.99%. This contributed to the annual value of -$5.0 for FY2025, which is 3575.99% up from last year.
- According to the latest figures from Q4 2025, Ascendis Pharma A's Debt to Equity is -$5.0, which was up 3575.99% from -$7.79 recorded in Q4 2024.
- In the past 5 years, Ascendis Pharma A's Debt to Equity registered a high of $2.07 during Q4 2022, and its lowest value of -$7.79 during Q4 2024.
- Moreover, its 5-year median value for Debt to Equity was $0.51 (2021), whereas its average is -$1.38.
- In the last 5 years, Ascendis Pharma A's Debt to Equity soared by 164387.14% in 2022 and then tumbled by 28236.91% in 2023.
- Ascendis Pharma A's Debt to Equity (Quarter) stood at $0.12 in 2021, then soared by 1643.87% to $2.07 in 2022, then tumbled by 282.37% to -$3.78 in 2023, then crashed by 106.17% to -$7.79 in 2024, then skyrocketed by 35.76% to -$5.0 in 2025.
- Its Debt to Equity stands at -$5.0 for Q4 2025, versus -$7.79 for Q4 2024 and -$3.78 for Q4 2023.